Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Cybin Inc. CYBN

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Begin Trading on NYSE American

Posted on August 4, 2021 by MissionIR

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that on  trading opens on Aug. 5, 2021, its common shares will be trading on the NYSE American LLC stock exchange; the shares will trade … Continue reading →

Posted in Cybin Inc. CLXPF, Cybin Inc. CYBN, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Receives Listing Approval from NYSE American

Posted on July 22, 2021 by MissionIR

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, will be moving exchanges. The company has announced that it  received conditional listing approval from the NYSE American LLC stock exchange. The NYSE American is designed for … Continue reading →

Posted in Cybin Inc. CLXPF, Cybin Inc. CYBN, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces Annual Financial Results, Business Highlights and Adelia Milestones

Posted on June 28, 2021 by MissionIR

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today released financial and business highlights for its financial year ended March 31, 2021. “It has been an incredibly busy and successful year for the Cybin team, … Continue reading →

Posted in Cybin Inc. CLXPF, Cybin Inc. CYBN, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces Advancement of IND-Enabling Studies of Psychedelic Molecules for IND Applications

Posted on April 13, 2021 by MissionIR

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has plans to advance the preclinical work for two of its deuterated tryptamine development candidates: its orally dissolving tablet (“ODT”) formulation of CYB003 and its inhaled formulation … Continue reading →

Posted in Cybin Inc. CYBN | Leave a comment

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Completes Pre-Clinical Studies, Progresses Two Drug Candidates

Posted on April 6, 2021 by MissionIR

Cybin has completed more than 20 pre-clinical studies in record time. Company is advancing two new therapeutic candidates with enhanced, improved properties. Drug candidates are designed to treat serious psychiatric conditions with high unmet medical needs. Cybin (NEO: CYBN) (OTCQB: … Continue reading →

Posted in Cybin Inc. CLXPF, Cybin Inc. CYBN | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Appoints New Management Positions, Focused on Development and Clinical Operations

Posted on March 30, 2021 by MissionIR

Cybin (NEO: CYBN) (OTCQB: CLXPF) announced changes in senior management positions. Cybin US Holdings Inc.’s new chief clinical officer will be Alexander Belser, PhD and its new chief operating officer will be Aaron Bartlone. In addition, co-founder and former COO … Continue reading →

Posted in Cybin Inc. CYBN | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Enters Strategic Drug Development Agreement with Catalent Inc. (NYSE: CTLT)

Posted on March 22, 2021 by MissionIR

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced its entry into a drug development agreement with Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, … Continue reading →

Posted in Cybin Inc. CLXPF, Cybin Inc. CYBN | Leave a comment

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Upsizes Its Bought Deal Offering Due to Surge in Demand

Posted on March 9, 2021 by MissionIR

Cybin’s latest offering generated exceptional demand; announces upsize of “bought deal” offering Burgeoning psychedelic sector attracts investors’ attention as compound may prove effective in mental health treatments. Cybin appears set for rapid growth as research accelerates, public acceptance grows. Cybin … Continue reading →

Posted in Cybin Inc. CLXPF, Cybin Inc. CYBN | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTC: CLXPF) to Leverage Breakthrough Tech to Measure Real-Time Brain Activity During Psychedelic Experiences

Posted on February 19, 2021 by MissionIR

Cybin (NEO: CYBN) (OTC: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently announced its collaboration with neurotech pioneer HI LLC dba Kernel. According to the update, CYBN will leverage Kernel Flow, Kernel’s breakthrough … Continue reading →

Posted in Cybin Inc. CYBN | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTC: CLXPF) Announces Upcoming Conference Call, Webcast to Provide Business Update

Posted on February 11, 2021 by MissionIR

Cybin (NEO: CYBN) (OTC: CLXPF), a life sciences company focused on psychedelic pharmaceutical therapies, has scheduled a conference call and webcast for 10 a.m. ET on Wednesday, Feb. 17, 2021. Cybin CEO Doug Drysdale will conduct the call and webcast. … Continue reading →

Posted in Cybin Inc. CYBN, MissionIRNewsBreaks | Leave a comment